398 related articles for article (PubMed ID: 33547844)
1. Levodopa Causes Striatal Cholinergic Interneuron Burst-Pause Activity in Parkinsonian Mice.
Paz RM; Tubert C; Stahl AM; Amarillo Y; Rela L; Murer MG
Mov Disord; 2021 Jul; 36(7):1578-1591. PubMed ID: 33547844
[TBL] [Abstract][Full Text] [Related]
2. D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
Paz RM; Stahl AM; Rela L; Murer MG; Tubert C
Mov Disord; 2022 Aug; 37(8):1693-1706. PubMed ID: 35535012
[TBL] [Abstract][Full Text] [Related]
3. Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia.
Lim SAO; Xia R; Ding Y; Won L; Ray WJ; Hitchcock SA; McGehee DS; Kang UJ
Neurobiol Dis; 2015 Apr; 76():67-76. PubMed ID: 25661301
[TBL] [Abstract][Full Text] [Related]
4. The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia.
Castello J; Cortés M; Malave L; Kottmann A; Sibley DR; Friedman E; Rebholz H
Sci Rep; 2020 Feb; 10(1):2542. PubMed ID: 32054879
[TBL] [Abstract][Full Text] [Related]
5. What's wrong with the striatal cholinergic interneurons in Parkinson's disease? Focus on intrinsic excitability.
Tubert C; Murer MG
Eur J Neurosci; 2021 Apr; 53(7):2100-2116. PubMed ID: 32302030
[TBL] [Abstract][Full Text] [Related]
6. Decrease of a Current Mediated by Kv1.3 Channels Causes Striatal Cholinergic Interneuron Hyperexcitability in Experimental Parkinsonism.
Tubert C; Taravini IRE; Flores-Barrera E; Sánchez GM; Prost MA; Avale ME; Tseng KY; Rela L; Murer MG
Cell Rep; 2016 Sep; 16(10):2749-2762. PubMed ID: 27568555
[TBL] [Abstract][Full Text] [Related]
7. Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
Ztaou S; Maurice N; Camon J; Guiraudie-Capraz G; Kerkerian-Le Goff L; Beurrier C; Liberge M; Amalric M
J Neurosci; 2016 Aug; 36(35):9161-72. PubMed ID: 27581457
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of striatal cholinergic interneuron activity by the Kv7 opener retigabine and the nonsteroidal anti-inflammatory drug diclofenac.
Paz RM; Tubert C; Stahl A; Díaz AL; Etchenique R; Murer MG; Rela L
Neuropharmacology; 2018 Jul; 137():309-321. PubMed ID: 29758221
[TBL] [Abstract][Full Text] [Related]
9. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
[TBL] [Abstract][Full Text] [Related]
10. Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
Perez XA; Zhang D; Bordia T; Quik M
Mov Disord; 2017 Apr; 32(4):538-548. PubMed ID: 28256010
[TBL] [Abstract][Full Text] [Related]
11. Alterations in the intrinsic properties of striatal cholinergic interneurons after dopamine lesion and chronic L-DOPA.
Choi SJ; Ma TC; Ding Y; Cheung T; Joshi N; Sulzer D; Mosharov EV; Kang UJ
Elife; 2020 Jul; 9():. PubMed ID: 32687053
[TBL] [Abstract][Full Text] [Related]
12. Cholinergic control of striatal neurons to modulate L-dopa-induced dyskinesias.
Bordia T; Perez XA
Eur J Neurosci; 2019 Mar; 49(6):859-868. PubMed ID: 29923650
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited.
Paz RM; Murer MG
Neuroscience; 2021 Jul; 467():201-217. PubMed ID: 34048797
[TBL] [Abstract][Full Text] [Related]
14. A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia.
Conti MM; Chambers N; Bishop C
Neurosci Biobehav Rev; 2018 Sep; 92():67-82. PubMed ID: 29782883
[TBL] [Abstract][Full Text] [Related]
15. Striatal synaptic adaptations in Parkinson's disease.
Shen W; Zhai S; Surmeier DJ
Neurobiol Dis; 2022 Jun; 167():105686. PubMed ID: 35272023
[TBL] [Abstract][Full Text] [Related]
16. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
17. Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystonia.
Scarduzio M; Zimmerman CN; Jaunarajs KL; Wang Q; Standaert DG; McMahon LL
Exp Neurol; 2017 Sep; 295():162-175. PubMed ID: 28587876
[TBL] [Abstract][Full Text] [Related]
18. The striatal cholinergic system in L-dopa-induced dyskinesias.
Perez XA; Bordia T; Quik M
J Neural Transm (Vienna); 2018 Aug; 125(8):1251-1262. PubMed ID: 29492663
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of Haloperidol-Induced Catalepsy by GPR143, an L-Dopa Receptor, in Striatal Cholinergic Interneurons.
Arai M; Suzuki E; Kitamura S; Otaki M; Kanai K; Yamasaki M; Watanabe M; Kambe Y; Murata K; Takada Y; Arisawa T; Kobayashi K; Tajika R; Miyazaki T; Yamaguchi M; Lazarus M; Hayashi Y; Itohara S; de Kerchove d'Exaerde A; Nawa H; Kim R; Bito H; Momiyama T; Masukawa D; Goshima Y
J Neurosci; 2024 Mar; 44(11):. PubMed ID: 38286627
[TBL] [Abstract][Full Text] [Related]
20. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
